SAM CHUN DANG PHARM. CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 106,600 KRW | +1.81% |
|
+3.80% | +37.90% |
| Sales 2022 | 177B 129M 10.32B | Sales 2023 | 193B 140M 11.22B | Capitalization | 1,759B 1.28B 102B |
|---|---|---|---|---|---|
| Net income 2022 | 5.84B 4.24M 340M | Net income 2023 | -10.38B -7.55M -604M | EV / Sales 2022 | 5.4 x |
| Net cash position 2022 | 9.66B 7.02M 562M | Net cash position 2023 | 39.12B 28.44M 2.28B | EV / Sales 2023 | 8.93 x |
| P/E ratio 2022 |
166
x | P/E ratio 2023 |
-167
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.41% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.81% | ||
| 1 week | +3.80% | ||
| Current month | -24.18% | ||
| 1 month | -24.07% | ||
| 3 months | +56.08% | ||
| 6 months | +66.04% | ||
| Current year | +37.90% |
1 week
99 300.00
110 800.00
1 month
95 400.00151 200.00
Current year
61 900.00151 200.00
1 year
49 750.00151 200.00
3 years
26 100.00151 200.00
5 years
21 350.00151 200.00
10 years
5 150.00151 200.00
| Managers | Title | Age | Since |
|---|---|---|---|
In-Seok Jeon
CEO | Chief Executive Officer | 50 | - |
Dae-In Yoon
CHM | Chairman | 74 | - |
Sae-Young Chun
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dae-In Yoon
CHM | Chairman | 74 | - |
In-Seok Jeon
CEO | Chief Executive Officer | 50 | - |
Yong-Gwan Kim
BRD | Director/Board Member | 59 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.59% | 2 M€ | -14.14% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +1.11% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 106,600 | +1.81% | 860,094 |
| 25/04/24 | 104,700 | -3.50% | 610,537 |
| 24/04/24 | 108,500 | +6.69% | 1,157,709 |
| 23/04/24 | 101,700 | +1.50% | 597,164 |
| 22/04/24 | 100,200 | -2.43% | 906,728 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
SAM CHUN DANG PHARM. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Companyâs products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.
Sector
Pharmaceuticals
Calendar
12/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +37.90% | 1.76B | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- A000250 Stock
